Prednisone Drug Study

Download as docx, pdf, or txt
Download as docx, pdf, or txt
You are on page 1of 2

Prednisone Drug Study

In making a Drug Study, the following elements must be present:Generic


Name and the Brand name (not all brands, just the brand used by the
patient), Action, Indication, Pregnancy Category, Drug Classification, and
Contraindication, Adverse Effect, Drug interaction and Nursing
Consideration/Intervention. Most clinical instructors preferred this to be in
a long bond paper in printed or handwritten with paper in landscape.
Prednisone
Brand Name: Apo-Prednisone (CAN), Deltasone, Liquid Pred, Meticorten,
Novo-Prednisone (CAN), Orasone, Panasol-S, Prednicen-M, PrednisoneIntensol, Sterapred DS, Winpred (CAN)
Pregnancy Category C
Drug classes: Corticosteroid (intermediate acting), Glucocorticoid, Hormone
Therapeutic actions
Enters target cells and binds to intracellular corticosteroid receptors, thereby
initiating many complex reactions that are responsible for its antiinflammatory and immunosuppressive effects.
Indications
Replacement therapy in adrenal cortical insufficiency
Hypercalcemia associated with cancer
Short-term management of various inflammatory and allergic disorders,
such as rheumatoid arthritis, collagen diseases (eg, SLE), dermatologic
diseases
(eg, pemphigus), status asthmaticus, and autoimmune disorders
Hematologic disorders: thrombocytopenia purpura, erythroblastopenia
Ulcerative colitis, acute exacerbations of multiple sclerosis and palliation in
some leukemias and lymphomas
Trichinosis with neurologic or myocardial involvement
Contraindications
Contraindicated with infections, especially tuberculosis, fungal infections,
amebiasis, vaccinia and varicella, and antibiotic-resistant infections;
lactation.
Adverse effects

Vertigo, headache, paresthesias, insomnia, convulsions, psychosis, cataracts,


increased intraocular pressure, glaucoma (long-term therapy)
Hypotension, shock, hypertension and CHF secondary to fluid retention,
thromboembolism, thrombophlebitis, fat embolism, cardiac arrhythmias
Na+ and fluid retention, hypokalemia, hypocalcemia
Amenorrhea, irregular menses, growth retardation, decreased carbohydrate
tolerance, diabetes mellitus, cushingoid state (long-term effect), increased
blood sugar, increased serum cholesterol, decreased T3 and T4 levels, HPA
suppression with systemic therapy longer than 5 days
Peptic or esophageal ulcer, pancreatitis, abdominal distention, nausea,
vomiting, increased appetite, weight gain (long-term therapy)
Hypersensitivity or anaphylactoid reactions
Drug Interactions:
Increased therapeutic and toxic effects with troleandomycin, ketoconazole
Increased therapeutic and toxic effects of estrogens, including hormonal
contraceptives
Risk of severe deterioration of muscle strength in myasthenia gravis
patients who also are receiving ambenonium, edrophonium, neostigmine,
pyridostigmine
Decreased steroid blood levels with barbiturates, phenytoin, rifampin
Decreased effectiveness of salicylates
Nursing considerations
Administer once-a-day doses before 9 AM to mimic normal peak
corticosteroid blood levels.
Increase dosage when patient is subject to stress.
Taper doses when discontinuing high-dose or long-term therapy.
Do not give live virus vaccines with immunosuppressive doses of
corticosteroids.

You might also like